If you are interested in the answers to the questions from the MSTCG, which were mainly German-speaking Neuros read on it is open access
Wiendl, H., Gold, R., Zipp, F. et al. Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. Neurol. Res. Pract. 3, 44 (2021). https://doi.org/10.1186/s42466-021-00140-1
Question 1: when should disease-modifying immunotherapy be initiated? Before or after the onset of disability? Already with CIS (e.g., isolated optic neuritis)?
Question 2: which disease-modifying therapy should be selected when? Should a less potent and low-risk therapy initially be selected for all patients, or should some patients immediately receive a high-efficacy therapy with a higher risk profile and requiring more complex monitoring? To be considered in this context: escalation in three stages versus individually adjusted escalation
Question 3: when should the immunotherapy be terminated? Should the therapy generally be terminated after a few  years, or is long-term and sometimes permanent therapy feasible? To be considered in this context: the problem of disease reactivation/rebound
Question 4: how strongly should aspects specified in the official therapy approval be reflected in a treatment recommendation? To be considered in this context: is the equivalent recommendation for rituximab (off-label use) and ocrelizumab as approved B-cell-depleting therapy (on-label) appropriate?
If we could herd cats I wonder what the Engrish-spreaking neuro view would be
Was würder ProfK sagen?
Disclaimer: Please note that the opinions expressed here are those of the author and do not reflect the positions of the Barts and The London School of Medicine and Dentistry nor Barts Health NHS Trust or Queen Mary Univeristy of London.